Open AccessMyelodysplastic syndrome from theoretical review to clinical application view
Author(s) -
Amrallah A. Mohammad
Publication year - 2018
Publication title -
oncology reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.637
H-Index - 21
eISSN - 1970-5565
pISSN - 1970-5557
DOI - 10.4081/oncol.2018.397
Subject(s) - medicine , myelodysplastic syndromes , food and drug administration , bone marrow failure , intensive care medicine , myeloid leukemia , disease , bone marrow , drug , hematology , haematopoiesis , pharmacology , stem cell , biology , genetics
Myelodysplastic syndromes (MDS), called ineffective hematopoiesis is indicated by bone marrow failure and tendency to acute myeloid leukemia transformation. Since the disease is more common in elderly with non- hematology co-morbidities, the research for less toxic and curative novel agents is essential. More than 12 years without new Food and Drug Administration approved drugs in MDS management through the whole course, only 5 drugs. We summarized the basic data in diagnosis, treatment guidelines and future direction.